SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.07%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.36B
AUM Growth
+$1.36B
(+13%)
Cap. Flow
+$221M
Cap. Flow
% of AUM
16.22%
Top 10 Holdings %
Top 10 Hldgs %
57.49%
Holding
75
New
17
Increased
12
Reduced
20
Closed
14
Top Buys
| 1 |
Gilead Sciences
GILD
|
$71.5M |
| 2 |
AbbVie
ABBV
|
$63.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
$52.1M |
| 4 |
Stryker
SYK
|
$41.8M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$38.9M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$86.5M |
| 2 |
Elanco Animal Health
ELAN
|
$51.7M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.5M |
| 4 |
Incyte
INCY
|
$13.1M |
| 5 |
Edwards Lifesciences
EW
|
$12.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Savara
SVRA
$567M
| $16.8M | 1.22% | 5,471,299 -191,251 | -3% | -$587K |
|
27
Janux Therapeutics
JANX
$1.37B
| $13.6M | 0.99% | 253,262 +88,492 | +54% | +$4.74M |
|
|
BIOA
28
BioAge Labs, Inc. Common Stock
BIOA
$177M
| $13.3M | 0.97% | 2,304,901 | – | – |
|
|
INZY
29
DELISTED
Inozyme Pharma
INZY
| $11.9M | 0.86% | 4,280,308 | – | – |
|
30
Eli Lilly
LLY
$657B
| $11.1M | 0.81% | +14,364 | New | +$11.1M |
|
31
Edgewise Therapeutics
EWTX
$1.51B
| $10.8M | 0.78% | 402,773 +18,006 | +5% | +$481K |
|
32
Pharvaris
PHVS
$1.39B
| $10.7M | 0.78% | 560,723 -39,579 | -7% | -$759K |
|
|
JBIO
33
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $9.96M | 0.73% | 3,758,686 | – | – |
|
|
NARI
34
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $9.21M | 0.67% | 180,456 +90,129 | +100% | +$4.6M |
|
35
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.71M | 0.63% | 658,627 -128,372 | -16% | -$1.7M |
|
36
Inhibrx
INBX
$408M
| $8.12M | 0.59% | 527,190 -8,878 | -2% | -$137K |
|
37
Immunome
IMNM
$828M
| $7.93M | 0.58% | 746,824 +70,058 | +10% | +$744K |
|
38
Cogent Biosciences
COGT
$1.69B
| $6.42M | 0.47% | 823,160 -1,442,070 | -64% | -$11.2M |
|
39
Achieve Life Sciences
ACHV
$152M
| $4.6M | 0.34% | 1,306,482 -207,550 | -14% | -$731K |
|
40
Erasca
ERAS
$445M
| $4.51M | 0.33% | 1,795,880 -46,788 | -3% | -$117K |
|
41
Establishment Labs
ESTA
$1.2B
| $4.39M | 0.32% | 95,305 -86,171 | -47% | -$3.97M |
|
42
Avantor
AVTR
$9.18B
| $4.21M | 0.31% | +200,000 | New | +$4.21M |
|
|
43
Edwards Lifesciences
EW
$47.8B
| $2.96M | 0.22% | 40,000 -162,898 | -80% | -$12.1M |
|
44
Exact Sciences
EXAS
$8.98B
| $2.92M | 0.21% | 52,042 +14,405 | +38% | +$809K |
|
45
Immatics
IMTX
$619M
| $2.44M | 0.18% | 343,206 -42,894 | -11% | -$305K |
|
46
Danaher
DHR
$147B
| $2.3M | 0.17% | +10,000 | New | +$2.3M |
|
47
NextCure
NXTC
$13.5M
| $2.06M | 0.15% | 2,671,856 | – | – |
|
48
AnaptysBio
ANAB
$569M
| $1.76M | 0.13% | +132,927 | New | +$1.76M |
|
49
Keros Therapeutics
KROS
$618M
| $1.51M | 0.11% | +95,375 | New | +$1.51M |
|
50
Bolt Biotherapeutics
BOLT
$9.85M
| $1.47M | 0.11% | 2,754,437 | – | – |
|